海思科(002653.SZ):創新藥HSK31679片獲批臨牀,治療成人原發性高膽固醇血癥
格隆匯2月7日丨海思科(002653.SZ)公佈,公司近日獲得國家藥監局藥品審評中心下發的關於HSK31679片的《藥物臨牀試驗批准通知書》。經審查,2021年11月受理的HSK31679片符合藥品註冊的有關要求,同意該藥品開展“擬用於治療成人原發性高膽固醇血癥”的臨牀試驗。
HSK31679片是公司自主研發的一種高選擇性甲狀腺激素β受體(THR-β)激動劑,通過與甲狀腺激素β受體結合,影響脂代謝過程中的關鍵步驟,起到降低膽固醇的作用,有較好的開發前景,將為眾多高膽固醇血癥患者提供一種新的更優治療選擇,具有重要的臨牀和社會意義。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.